MacroGenics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.

CEO

Eric Risser

CEOEric Risser

Employees

341

Employees341

Headquarters

Rockville, Maryland

HeadquartersRockville, Maryland

Founded

2000

Founded2000

Employees

341

Employees341

MGNX Key Statistics

Market cap

93.23M

Market cap93.23M

Price-Earnings ratio

-2.71

Price-Earnings ratio-2.71

Dividend yield

—

Dividend yield—

Average volume

1.15M

Average volume1.15M

High today

$1.61

High today$1.61

Low today

$1.47

Low today$1.47

Open price

$1.56

Open price$1.56

Volume

1.06M

Volume1.06M

52 Week high

$5.10

52 Week high$5.10

52 Week low

$0.9897

52 Week low$0.9897

MGNX News

TipRanks 10h

MacroGenics assumed with an Overweight at Barclays

Barclays analyst Etzer Darout assumed coverage of MacroGenics (MGNX) with an Overweight rating and $3 price target The firm believes MGC026 could drive share up...

Analyst ratings

67%

of 6 ratings

Buy

33.3%

Hold

66.7%

Sell

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.